Off-the-shelf CAR natural killer progenitor cell therapies are built to last - PubMed
5 days ago
- #immunotherapy
- #progenitor cells
- #CAR NK cells
- Off-the-shelf CAR natural killer (NK) progenitor cell therapies are designed for long-term persistence.
- Induced pluripotent stem cell (iPSC)-derived CAR NK cells are a new class of immunotherapy but face limitations due to short-term persistence.
- Wang et al. developed a lineage-committed progenitor cell therapy platform to sustain in vivo CAR iNK cell lymphopoiesis and improve tumor control.
- The study highlights potential conflicts of interest related to CAR T cell therapy and targeted protein degradation patents.